New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations


  • Study

    Phase II, single-arm, multicohort (RAGNAR)
    Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4 alterations and disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them
    Erdafitinib (n=217)




  • Efficacy

    oRR: 30% [64 of 217 pts]
    12mos PFS: 15.4 % vs 0%
    mPFS: 4.0 vs. 2.5 mos, HR:0.48, p=0.007



  • Safety

    Grade3 Aes: Stomatitis (12%), hyperphosphatemia (5%), palmar–plantar erythrodysaesthesia syndrome (6%)



  • JAMA Oncol. 2023;24(8):925-935, AUG 2023

    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    http://doi.org/10.1016/S1470-2045(23)00275-9

    Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023